V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough

Innoviva Executive Compensation (FY25)

INVA · Executive and director compensation, fiscal 2025 only

The Innoviva brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Data as of September 7, 2026Latest filing (8-K): May 4, 2026
12 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Innoviva brief$1,500Get the executive brief
161 figures on this page: 150 cited to the filing that reported them, 11 calculated from figures it prints. See the citations
Chief executive, fiscal 2025
◇
Pavel Raifeld
Latest say-on-pay support
=
May 4, 2026

Frequently asked questions

Answers drawn from the data on this page.
Who is Innoviva's chief executive and what were they paid?
Total compensation for Pavel Raifeld, Chief Executive Officer, came to $5,400,197 in fiscal 2025.
What was Innoviva's say-on-pay result?
Shareholders recorded 95.0% support for the say-on-pay proposal at the meeting held May 4, 2026 for fiscal 2025.
Which companies are in Innoviva's peer group?
The disclosed peer group names Agios Pharmaceuticals, Inc., Amarin Corporation plc, Arvinas, Inc., Catalyst Pharmaceuticals, Inc. and Cogent Biosciences, Inc., among others.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Pavel Raifeld
Chief Executive Officer
◇◇◇◇——◇◇
Stephen Basso
Chief Financial Officer and President of IST
◇◇◇◇——◇— not reconciled
Marianne Zhen
Chief Accounting Officer
◇◇◇◇——◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Marianne ZhenRSU◇——◇——◇
Marianne ZhenOPTION◇——◇—◇◇
Pavel RaifeldRSU◇——◇——◇
Pavel RaifeldRSU◇——◇——◇
Pavel RaifeldOPTION◇——◇—◇◇
Stephen BassoOPTION◇——◇—◇◇
Stephen BassoRSU◇——◇——◇
Stephen BassoRSU◇——◇——◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Marianne ZhenRSU◇◇——
RSU◇◇——
Option◇—◇—
RSU◇◇——
Option◇—◇—
Option◇—◇—
RSU◇◇——
Option◇—◇—
Pavel RaifeldOption◇—◇—
Option◇—◇—
RSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
Stephen BassoOption◇—◇—
RSU◇◇——
Option◇—◇—
Option◇—◇—
RSU◇◇——
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Jules Haimovitz
◇◇◇———◇
Mark A. DiPaolo
◇◇◇———◇
Sarah J. Schlesinger
◇◇◇———◇
Derek A. Small
◇◇◇———◇
Sapna Srivastava
◇—————◇
Odysseas D. Kostas
◇—————◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as restricted stock units.
Stock ownership guideline: 10x base annual cash retainer ($500,000)

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Agios Pharmaceuticals, Inc. AGIO
  • Amarin Corporation plc AMRN
  • Arvinas, Inc. ARVN
  • Catalyst Pharmaceuticals, Inc. CPRX
  • Cogent Biosciences, Inc. COGT
  • Coherus BioSciences, Inc. CHRS
  • Ligand Pharmaceuticals Inc. LGND
  • MacroGenics, Inc. MGNX
  • Morphic Holding, Inc. MORF
  • Savara Inc. SVRA
  • SpringWorks Therapeutics, Inc. SWTX
  • Theravance Biopharma, Inc. TBPH
  • Travere Therapeutics, Inc. TVTX
  • Verona Pharma plc VRNA
  • Xencor, Inc. XNCR
  • Xeris Biopharma Holdings, Inc. XERS

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025May 4, 2026=◇◇◇
2024May 19, 2025=◇◇◇
2023June 17, 2024=◇◇◇
2022May 22, 2023=◇◇◇
2021April 25, 2022=◇◇◇
2020May 14, 2021=◇◇◇
2019April 24, 2020=◇◇◇
2018April 24, 2019=◇◇◇
2017April 24, 2018=◇◇◇
2016April 20, 2017=◇◇◇
2015April 26, 2016=◇◇◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Innoviva files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Innoviva disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Innoviva sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Innoviva's disclosed peer group is defensible, who names Innoviva back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
161 figures on this page: 150 cited to the filing that reported them, 11 calculated from figures it prints.
150 cited to the filing
11 calculated from the filing

Documents cited

  1. 0001193125-26-204243
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001140361-26-010912
    DIRECTOR COMPENSATION & · Director Compensation · Grants of Plan-Based Awards · Outstanding Equity Awards at 2025 Fiscal Year-End · and 2 more sections
  3. 0001104659-25-051614
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0001104659-24-073416
    Item 5.07 Submission of Matters to a Vote of Security Holders
  5. 0001104659-23-063704
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0000899140-22-000487
    Item 5.07 Submission of Matters to a Vote of Security Holders
  7. 0001104659-21-069933
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0001104659-20-052385
  9. 0001104659-19-023738
  10. 0001104659-18-026920
  11. 0001104659-17-026367
    Item 5.07 Submission of Matters to a Vote of Security Holders
  12. 0001104659-16-115299
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Innoviva executive compensation, FY2025.” https://intel.velarion.ai/comp/INVA (accessed 2026).
Short form: data: Velarion

The Innoviva brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
12 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Innoviva and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Peers Innoviva discloses

The companies named in INVA's own disclosed peer group.

Agios Pharmaceuticals, Inc.Amarin Corporation plcArvinas, Inc.Catalyst Pharmaceuticals, Inc.Cogent Biosciences, Inc.Coherus BioSciences, Inc.Ligand Pharmaceuticals Inc.MacroGenics, Inc.Morphic Holding, Inc.Savara Inc.SpringWorks Therapeutics, Inc.Theravance Biopharma, Inc.Travere Therapeutics, Inc.Xencor, Inc.Xeris Biopharma Holdings, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy